A news story published on March 14 (South Africa awards antiretroviral supply contracts) contained an error regarding the price of Kaletra. Abbott Laboratories has asked us to point out that the price of Kaletra (lopinavir/ritonavir) in South Africa will remain fixed at $500 throughout the period of the contract and will not increase by 32% over two years, as originally stated in Business Day on March 4, 2005.